Immunovia announces intention to apply for listing on Nasdaq Stockholm's Main Market
The Board of Immunovia AB (publ) ("Immunovia" or the "Company") today announces its intention to apply during the first half of 2017 for a listing of its shares on Nasdaq Stockholm's Main Market. Immunovia’s shares are currently admitted for trading on the Nasdaq First North under the IMMNOV ticker.
"Our shareholder base has gradually become broader since our listing on the Nasdaq First North on December 1, 2015. With the listing of Immunovia’s shares on Nasdaq Stockholm Main Market we are now taking the next step to get access to the international capital market and making it easier for institutional investors to become owners of the Company as part of our continued business expansion," says Immunovia’s CEO Mats Grahn.
This information is such that Immunovia is required to disclose under EU Market Abuse Regulation 596/2014. The information was provided by the contact person below to be published on August 16 2016 at 8.30 CET.
For further information, please contact:
Mats Grahn, CEO, Immunovia AB
Phone: +46 (0) 70-532 02 30
E-mail: mats.grahn@immunovia.com
About Immunovia
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: www.immunovia.com)
Immunovia’s shares (IMMNOV) are listed on Nasdaq First North in Stockholm and Wildeco is the company’s Certified Adviser. For more information, please visit www.immunovia.com.
About Pancreatic Cancer
Pancreatic Cancer is one of the most deadly and difficult to detect cancers, as the signs and symptoms are diffuse and similar to other diseases. There are more than 40,000 deaths and over 50,000 new cases diagnosed each year in the U.S. alone, and the five-year survival rate for pancreatic cancer is currently 4-6%. It is predicted to become the second leading cause of cancer death by 2020. However, because resection is more successful in stage I/II, can significantly improve pancreatic cancer patients’ 5-year survival rates from 4-6% to potentially 50-60%.
###
Tags: